Results 121 to 130 of about 8,452 (228)

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8724-8728, September 2026.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection‐related mortality remains a significant concern for patients' overall survival (OS). Methods This Swedish, population‐based study examined incidence of infections and OS in
Ingrid Glimelius, Love Tätting, Jonatan Freilich, M. Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurður Y. Kristinsson   +6 more
wiley   +1 more source

RWE Aktiengesellschaft. Geschaeftsbericht 1991/92 [PDF]

, 1992
Copy held by FIZ Karlsruhe; available from UB/TIB Hannover / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische ...
Rheinisch-Westfaelisches Elektrizitaetswerk A.G. (RWE), Essen (Germany)
core  

Fundamental analysis of RWE [PDF]

, 2020
The goal of this bachelor thesis is a fundamental analysis of the company RWE. The first part examines the impact of macroeconomic variables on the stock price.
Kocourek, Ivan
core  

The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Objectives: To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. Methods: We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study.
Dominic Culligan, Adele Taylor, Alexandra Smith, Catherine Cargo, Howard Oster, Argiris Symeonidis, Reinhard Stauder, Saskia Langemeijer, Luca Malcovati, Pierre Fenaux, Jaroslav Čermák, Eva Hellström‐Lindberg, Juliet Mills, Ioannis Kotsianidis, Maud D'Aveni, Corine van Marrewijk, Marlijn Hoeks, Theo de Witte, David Bowen, Moshe Mittelman   +19 more
wiley   +1 more source

RWE AG. Geschaeftsbericht 1990/91 [PDF]

, 1991
Available from FIZ Karlsruhe / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische ...
Rheinisch-Westfaelisches Elektrizitaetswerk A.G. (RWE), Essen (Germany)
core  

Persistence to Multiple Myeloma Treatments Given at First Relapse—Results From the Australian Real‐World OPTIMISE Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Daratumumab became publicly available in Australia in 2021 in combination with bortezomib and dexamethasone (DVd), as a second‐line (2L) therapy for multiple myeloma (MM). We evaluated real‐world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample ...
Felix Buescher, Steve Su, Ben Waterhouse, Cletus Pinto   +3 more
wiley   +1 more source

Active Safety Surveillance Using Real‐World Evidence (ASSURE) Implementation: Transparent and Reproducible Real‐World Evidence Standardized Framework to Support Safety Signal Evaluation

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose To summarize experience with Johnson & Johnson's novel Active Safety Surveillance Using Real‐world Evidence (ASSURE) program for producing efficient, transparent, applicable, and impactful RWE to support routine pharmacovigilance processes.
Kevin Haynes, Jenna Reps, Jill Hardin, Eva‐Maria Didden, James Gilbert, Joel Swerdel, Justin Bohn, Mitchell M. Conover, Amir Sarayani, Anthony G. Sena, Emily Yost, Valerie van Baalen, Kourtney Davis, Patrick Ryan, Martijn Schuemie   +14 more
wiley   +1 more source

Wertorientierte Unternehmensführung bei RWE

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung, 2000
The main concept of performance measurement in the RWE-Group is a rate of return on invested capital. A positive spread between the rate of return on invested capital and the cost of capital rate is the main value driver. The required target-return on invested capital for business units is determined by a benchmark analysis.
openaire   +1 more source

R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 27

Journal of Comparative Effectiveness Research
In this update, we review the US FDA’s updated compendium of real-world evidence (RWE) use in medical device regulatory decisions, a comprehensive scan of RWE utilization in Canadian drug reimbursement submissions, and Institute for Clinical and ...
Paul Arora, Sreeram V Ramagopalan
doaj   +1 more source